Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma. - Yee AJ; Laubach JP; Campagnaro EL; Lipe BC; Nadeem O; Friedman RS; Cole CE; O'Donnell EK; Bianchi G; Branagan AR; Schlossman RL; Shapiro SJ; et al. (Blood advances, 2025)